SynthesisPloS one2015
Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.Circulation · 2020Pooled it
- Acute effects of high intensity interval training versus moderate intensity continuous training on haemostasis in patients with coronary artery disease.Scientific reports · 2024Trial
- Trauma-triggered coronary embolism causing extensive anterolateral ST-segment elevation myocardial infarction in a young man with a mechanical aortic valve: a case report.European heart journal. Case reports · 2026Article
- Mevalonic acid exerts procoagulant effect by potentiating factor Xa.Natural products and bioprospecting · 2026Article
- Opium Addiction and Coagulation Factors in ST-Segment Elevation Myocardial Infarction (STEMI) Patients: Implications for Thrombosis and Cardiovascular Outcomes.Iranian journal of public health · 2025Article
- Activated partial thromboplastin time-based clot waveform analysis: a potential for application in acute myocardial infarction and its complications.Scientific reports · 2024Article
- Degree of COVID-19 severity and mortality in stroke: correlation of clinical and laboratory parameters.BMC neuroscience · 2024Article
- Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders.European journal of medical research · 2023Review
- Strategies for Therapeutic Amelioration of Aberrant Plasma ZnInternational journal of molecular sciences · 2022Review
- Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow.Research and practice in thrombosis and haemostasis · 2022Article
- Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.American journal of hematology · 2021Article
- Acute Viral Illnesses and Ischemic Stroke: Pathophysiological Considerations in the Era of the COVID-19 Pandemic.Stroke · 2021Review
- Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study.Thrombosis research · 2021Article
- Accelerated Spatial Fibrin Growth and Impaired Contraction of Blood Clots in Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2020Article
- Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic.International journal of stroke : official journal of the International Stroke Society · 2020Review
- Proteomics Reveals Plasma Biomarkers for Ischemic Stroke Related to the Coagulation Cascade.Journal of molecular neuroscience : MN · 2020Article
- Coagulation factor VIII, white matter hyperintensities and cognitive function: Results from the Cardiovascular Health Study.PloS one · 2020Article
- Detection of Citrullinated Fibrin in Plasma Clots of Rheumatoid Arthritis Patients and Its Relation to Altered Structural Clot Properties, Disease-Related Inflammation and Prothrombotic Tendency.Frontiers in immunology · 2020Article
- A Population-Based Study of Incidence, Presentation, Management and Outcome of Primary Thromboembolic Ischemia in the Upper Extremity.World journal of surgery · 2019Observational
- Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study.BMC cardiovascular disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHypercoagulability increases the risk of arterial thrombosis; however, this effect may differ between various manifestations of arterial disease.
methodsIn this study, we compared the effect of coagulation factors as measures of hypercoagulability on the risk of ischaemic stroke (IS) and myocardial infarction (MI) by performing a systematic review of the literature. The effect of a risk factor on IS (relative risk for IS, RRIS) was compared with the effect on MI (RRMI) by calculating their ratio (RRR = RRIS/RRMI). A relevant differential effect was considered when RRR was >1+ its own standard error (SE) or <1-SE.
resultsWe identified 70 publications, describing results from 31 study populations, accounting for 351 markers of hypercoagulability. The majority (203/351, 58%) had an RRR greater than 1. A larger effect on IS risk than MI risk (RRE>1+1SE) was found in 49/343 (14%) markers. Of these, 18/49 (37%) had an RRR greater than 1+2SE. On the opposite side, a larger effect on MI risk (RRR<1-1SE) was found in only 17/343 (5%) markers.
conclusionsThese results suggest that hypercoagulability has a more pronounced effect on the risk of IS than that of MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.